Qiong Yang

Summary

Publications

  1. pmc Efficacy and adverse effects of transdermal fentanyl and sustained-release oral morphine in treating moderate-severe cancer pain in Chinese population: a systematic review and meta-analysis
    Qiong Yang
    Department of Oncology, The Sun Yat sen Memorial Hospital, Sun Yat Sen University, 107 West Yanjiang Road, Guangzhou, Guangdong, 510120, China
    J Exp Clin Cancer Res 29:67. 2010
  2. doi request reprint Gemcitabine-based cytotoxic doublets chemotherapy for advanced pancreatic cancer: updated subgroup meta-analyses of overall survival
    De Rong Xie
    Department of Oncology, Sun Yat Sen Memorial Hospital, Sun Yat Sen University, Guangzhou, China
    Jpn J Clin Oncol 40:432-41. 2010
  3. ncbi request reprint [Indirect comparison of different adjuvant chemotherapies for stage II-III gastric cancer after D2 gastrectomy in Asian patients]
    Zhi Min Jiang
    Department of Oncology, The Sun Yat sen Memorial Hospital, Guangzhou 510120, China
    Zhonghua Wei Chang Wai Ke Za Zhi 16:534-7. 2013
  4. ncbi request reprint Overall survival of patients with advanced pancreatic cancer improved with an increase in second-line chemotherapy after gemcitabine-based therapy
    Yuan Dong Zhang
    Department of Oncology, Sun Yat Sen Memorial Hospital, Sun Yat Sen University Guangzhou, China
    JOP 12:131-7. 2011
  5. pmc No survival benefit from adding cetuximab or panitumumab to oxaliplatin-based chemotherapy in the first-line treatment of metastatic colorectal cancer in KRAS wild type patients: a meta-analysis
    Si Wei Zhou
    Department of Oncology, Sun Yat Sen Memorial Hospital, Key Laboratory of Malignant Tumor Gene Regulation and Target Therapy of Guangdong Higher Education Institutes, Sun Yat Sen University, Guangzhou, Guangdong, People s Republic of China
    PLoS ONE 7:e50925. 2012
  6. pmc Postoperative chemoradiotherapy versus postoperative chemotherapy for completely resected gastric cancer with D2 Lymphadenectomy: a meta-analysis
    Yuan Yuan Huang
    Department of VIP, Sun Yat sen University Cancer Center, Sun Yat Sen University, Guangzhou, PR China
    PLoS ONE 8:e68939. 2013
  7. ncbi request reprint [Meta-analysis on gemcitabine of fixed-dose rate infusion plus oxaliplatin as first-line therapy for advanced pancreatic cancer]
    De Rong Xie
    Department of Oncology, The Second Affiliated Hospital, Sun Yat Sen University, Guangzhou, Guangdong, 510120, RP China
    Ai Zheng 26:895-9. 2007

Collaborators

  • De Rong Xie
  • Si Wei Zhou
  • Zhi Min Jiang
  • Yuan Dong Zhang
  • Ying Wei
  • Yuan Yuan Huang
  • Yan Xian Chen
  • Bei Zhang
  • Wen Ma

Detail Information

Publications7

  1. pmc Efficacy and adverse effects of transdermal fentanyl and sustained-release oral morphine in treating moderate-severe cancer pain in Chinese population: a systematic review and meta-analysis
    Qiong Yang
    Department of Oncology, The Sun Yat sen Memorial Hospital, Sun Yat Sen University, 107 West Yanjiang Road, Guangzhou, Guangdong, 510120, China
    J Exp Clin Cancer Res 29:67. 2010
    ..Previous meta-analysis suggested that transdermal fentanyl was not inferior to sustained-release oral morphine in treating moderate-severe cancer pain with less adverse effects. Now, we updated the data and performed a systematic review...
  2. doi request reprint Gemcitabine-based cytotoxic doublets chemotherapy for advanced pancreatic cancer: updated subgroup meta-analyses of overall survival
    De Rong Xie
    Department of Oncology, Sun Yat Sen Memorial Hospital, Sun Yat Sen University, Guangzhou, China
    Jpn J Clin Oncol 40:432-41. 2010
    ..Previous meta-analyses showed a survival advantage with gemcitabine (GEM)-based combinations over GEM in advanced pancreatic cancer. Therefore, it would be valuable to explore the specific active regimens based on a subgroup meta-analysis...
  3. ncbi request reprint [Indirect comparison of different adjuvant chemotherapies for stage II-III gastric cancer after D2 gastrectomy in Asian patients]
    Zhi Min Jiang
    Department of Oncology, The Sun Yat sen Memorial Hospital, Guangzhou 510120, China
    Zhonghua Wei Chang Wai Ke Za Zhi 16:534-7. 2013
    ..To compare efficacy of different adjuvant chemotherapy regimens for stage II-III gastric cancer after D2 gastrectomy in Asian patients...
  4. ncbi request reprint Overall survival of patients with advanced pancreatic cancer improved with an increase in second-line chemotherapy after gemcitabine-based therapy
    Yuan Dong Zhang
    Department of Oncology, Sun Yat Sen Memorial Hospital, Sun Yat Sen University Guangzhou, China
    JOP 12:131-7. 2011
    ..In the last decade, gemcitabine-based regimen as first-line therapy has demonstrated low efficacy regarding overall survival benefit for patients with advanced pancreatic cancer...
  5. pmc No survival benefit from adding cetuximab or panitumumab to oxaliplatin-based chemotherapy in the first-line treatment of metastatic colorectal cancer in KRAS wild type patients: a meta-analysis
    Si Wei Zhou
    Department of Oncology, Sun Yat Sen Memorial Hospital, Key Laboratory of Malignant Tumor Gene Regulation and Target Therapy of Guangdong Higher Education Institutes, Sun Yat Sen University, Guangzhou, Guangdong, People s Republic of China
    PLoS ONE 7:e50925. 2012
    ....
  6. pmc Postoperative chemoradiotherapy versus postoperative chemotherapy for completely resected gastric cancer with D2 Lymphadenectomy: a meta-analysis
    Yuan Yuan Huang
    Department of VIP, Sun Yat sen University Cancer Center, Sun Yat Sen University, Guangzhou, PR China
    PLoS ONE 8:e68939. 2013
    ..The present meta-analysis aims to provide more evidence on the relative benefits of adjuvant therapies in this setting...
  7. ncbi request reprint [Meta-analysis on gemcitabine of fixed-dose rate infusion plus oxaliplatin as first-line therapy for advanced pancreatic cancer]
    De Rong Xie
    Department of Oncology, The Second Affiliated Hospital, Sun Yat Sen University, Guangzhou, Guangdong, 510120, RP China
    Ai Zheng 26:895-9. 2007
    ..This study was to evaluate the efficacy of GEM of fixed-dose rate infusion plus oxaliplatin (GEMOX regimen) as first-line therapy for advanced pancreatic cancer by meta-analysis...